This company listing is no longer active
9996 Stock Overview
Engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Peijia Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.82 |
| 52 Week High | HK$8.35 |
| 52 Week Low | HK$2.16 |
| Beta | 0.58 |
| 11 Month Change | 14.17% |
| 3 Month Change | n/a |
| 1 Year Change | -59.71% |
| 33 Year Change | -87.24% |
| 5 Year Change | n/a |
| Change since IPO | -90.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9996 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | -0.7% | -1.0% | -1.5% |
| 1Y | -59.7% | -35.3% | 13.6% |
Return vs Industry: 9996 underperformed the Hong Kong Medical Equipment industry which returned -45.8% over the past year.
Return vs Market: 9996 underperformed the Hong Kong Market which returned -2.3% over the past year.
Price Volatility
| 9996 volatility | |
|---|---|
| 9996 Average Weekly Movement | 11.2% |
| Medical Equipment Industry Average Movement | 9.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 9996's share price has been volatile over the past 3 months.
Volatility Over Time: 9996's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1,050 | Yi Zhang | www.peijiamedical.com |
Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusMax, an iteration steerable TAVR system; TaurusTrio, a TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymeric leaflet TAVR system; Trilogy, a TAVR System; HighLife, a transseptal mitral value replacement system; Sutra Hemi Valve, a TMV coaptation augmentation system; GeminiOne, a transcatheter edge-to-edge repair system; MonarQ which is transcatheter tricuspid valve replacement systems; TaurusAtlas, a transfemoral balloon catheter; TaurusExplora, a pre-shaped guidewire; and TaurusNavi, an introducer sheath. The company also offers Jasper and Presgo, that are detachable coils; Jasper SS detachable coil; intracranial adjunctive stents; SacSpeed, a balloon dilatation catheter; Tethys AS, an aspiration catheter; Syphonet, a stent retriever; Fastunnel, a balloon microcatheter; Fluxcap, a balloon guiding catheter; NeuroStellar, an intracranial stent; Presgo microcatheter and micro guidewire; Heralder guiding catheter and distal access catheter; Tethys, an intermediate catheter; and Jasper power supply.
Peijia Medical Limited Fundamentals Summary
| 9996 fundamental statistics | |
|---|---|
| Market cap | HK$1.90b |
| Earnings (TTM) | -HK$276.04m |
| Revenue (TTM) | HK$567.41m |
3.3x
P/S Ratio-6.8x
P/E RatioIs 9996 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9996 income statement (TTM) | |
|---|---|
| Revenue | CN¥517.46m |
| Cost of Revenue | CN¥146.18m |
| Gross Profit | CN¥371.28m |
| Other Expenses | CN¥623.02m |
| Earnings | -CN¥251.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 71.75% |
| Net Profit Margin | -48.65% |
| Debt/Equity Ratio | 11.4% |
How did 9996 perform over the long term?
See historical performance and comparison